Day Two

Thursday 13th December 2018

8:50 am Chair’s Opening Remarks

Rethinking RWE Strategy

9:00 am ‘IMPACCT’ Panel Discussion: Value Generation, RWE & Life Cycle Management – Distilling Strategy for Innovation


• In what stages of the drug life cycle does RWE have greatest impact?
• Establishing the right evidence generation plan that meets clinical, regulatory and commercial needs of a product:
• How to?
• Does it differ between big and small pharma?
• What’s the ROI vs. value generation?
• Driving internal collaboration for value-based evidence generation

9:45 am Can Pharma Save $1 Billion Through the Strategic Use of RWE?

  • Melvin Olson Global Head, RWD Strategy & Innovation, Novartis


• Reviewing current evidence needs and trends
• Introducing a framework for integrated evidence generation
• Revisiting IMSHealth (now IQVIA) claims that Pharma can save $1 billion through real-world evidence

10:15 am Morning Refreshments & Networking

10:45 am Impact of Real World Evidence Across the Life Cycle

  • Marla Curran Executive Director, Head of Biometrics & Medical Writing, Paratek Pharmaceuticals


• Synthesizing information and alignment: key data gaps, SWOT, functionspecific needs
• Discussing big pharma vs. small pharma
• Strategic planning framework: Challenges > Resolutions > Tactical Plan
• Exploring stakeholder engagement and prioritization
• The strength of evidence spectrum and optimizing trial/study designs

11:15 am Use of RWD Outside of Traditional Comparative Effectiveness Research

  • Ravi Iyer Director, Global HEOR , Teva Pharmaceuticals


• Using RWD in early phase of life-cycle development
• Presenting a case study in the use of real world data to support payer discussions
• Exploring opportunities and challenges associated with use of RWD in early phase of asset development and payer discussions

12:00 pm Mastermind Session: Supporting & Enhancing Product Life Cycle with Innovative Evidence Strategies


This session facilitates in-depth discussions among participants in an informal environment. After splitting into groups, participants will discuss key challenges and opportunities regarding the current RWE landscape in regards to its utilization across product life-cycle to drive innovation and more patient-facing outcomes.

12:45 pm Lunch & Networking

Driving Commercial Success & Supporting the Bringing of New Therapeutic Options to Market

1:45 pm Evidence Planning: Leveraging Innovation for Impact

  • Sandy Leonard Former VP, Medical Evidence & Observational Research , AstraZeneca


• Understanding evidence needs early in the product lifecycle
• Identifying opportunities to invest in innovative evidence to address gaps
• Leveraging evidence with key medical and payer audiences

2:15 pm What Does it Take to Substantiate a Million-Dollar Price Tag in Gene Therapy?


• Exploring the challenges with gene therapy market access
• Discussing how evidence requirements are more rigorous in gene therapy
• Establishing a very different business model for gene therapies

2:45 pm ‘IMPACCT’ Panel Discussion: Looking Outwards – Demonstrating Product Value & Improved Care Delivery with RWE

  • Frank Zhang VP, Head of Market Access, uniQure
  • Sandy Leonard Former VP, Medical Evidence & Observational Research , AstraZeneca


• Developing a suitable evidence framework to demonstrate product value and differentiation
• Addressing external stakeholders’ (payors, providers and patients) concerns as they increasingly seek to understand the effects of new products in the real-world setting
• Supporting decision-makers and payors with evidence that is better tailored to help them determine reimbursement policies and insurance coverage for new therapeutic options

3:30 pm Chair’s Closing Remarks